Synergy CHC (SNYRQ) AI Stock Analysis

116 Followers

Synergy CHC

(Other OTC:SNYRQ)

Select Model

Rating:37.6Underperform

Price Target:$0.01▲(4400.00% Upside)

Action:reiterated

Date:09/26/26

The score is driven primarily by very weak financial fundamentals—large losses, negative cash generation, and a highly stressed balance sheet with negative equity and heavy leverage versus assets. Technicals add further downside risk given the pronounced downtrend (price below all key moving averages and negative MACD). Valuation provides limited offset because the negative P/E reflects ongoing losses and there is no dividend yield data to support the stock.

Positive Factors

Stable Gross MarginA consistently high gross margin indicates the underlying GI therapy business retains meaningful gross profit generation despite current losses. If maintained, this provides a foundation for operating improvement, although the company must still control costs and restore positive earnings.

Negative Factors

Declining RevenueDeclining revenue weakens the company’s operating base and makes it harder to absorb fixed costs, support research and commercialization, or improve earnings through scale. Continued contraction would also reduce the resources available to address leverage and fund the business internally.

Synergy CHC (SNYRQ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $941.82K
Dividend Yield: ―
Average Volume (3M): 46.91M
Price to Earnings (P/E): -0.1
Beta (1Y): 0.63
Revenue Growth: -17.53%
EPS Growth: -221.57%
Country: US
Employees: 28
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Synergy CHC Business Overview & Revenue Model

Company Description

Synergy CHC Corp. operates as a distributor of diverse consumer health, beauty, and lifestyle merchandise across the United States, Canada, and the United Kingdom. The company's brand portfolio features FOCUSfactor, specializing in nutritional supple...

Synergy CHC Financial Statement Overview

Summary

Income statement, balance sheet, and cash flow metrics point to severe financial stress: TTM revenue is down (-8.8%), profitability is materially negative (net margin ~-41% with negative operating profit/EBITDA), and operating/free cash flow are negative. The balance sheet is the key risk with consistently negative equity and debt far exceeding the asset base (TTM assets ~$6.5M vs. debt ~$27.7M), implying elevated solvency and funding risk despite relatively steady gross margin (~67%).

Income Statement

24Negative

Balance Sheet

15Very Negative

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	30.38M	30.38M	34.83M	42.78M	38.41M	40.23M
Gross Profit	20.27M	20.30M	23.64M	32.08M	12.96M	25.55M
EBITDA	-6.16M	-6.17M	6.47M	10.84M	-25.81M	2.81M
Net Income	-12.34M	-12.34M	2.12M	6.34M	-32.63M	1.41M
Balance Sheet
Total Assets	10.16M	10.16M	16.34M	12.24M	18.54M	12.59M
Cash, Cash Equivalents and Short-Term Investments	2.62M	2.62M	687.92K	632.53K	1.93M	1.67M
Total Debt	26.81M	26.81M	27.52M	27.62M	22.83M	8.75M
Total Liabilities	33.29M	33.29M	32.97M	39.55M	52.06M	16.27M
Stockholders Equity	-23.13M	-23.13M	-16.63M	-27.31M	-33.52M	-3.68M
Cash Flow
Free Cash Flow	-2.59M	-2.59M	-4.80M	421.73K	-8.43M	-1.59M
Operating Cash Flow	-2.59M	-2.59M	-4.80M	421.73K	-8.43M	-1.59M
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	4.65M	4.65M	4.80M	-2.09M	8.96M	1.95M

Synergy CHC Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SNYRQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GEG	49Neutral	$66.32M	-2.04	-75.26%	―	-12.05%	-831.33%
SNYRQ	38Underperform	$4,142	-0.06	91.30%	―	-17.53%	-221.57%
RDGT	33Underperform	$4.03M	-0.00	-3.54%	―	10.16%	98.05%

* Healthcare Sector Average

Performance Comparison

SNYRQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SNYRQ	Synergy Chc Corp	0.01	-1.97	-99.49%
RDGT	Ridgetech, Inc.	1.16	-607.84	-99.81%
GEG	Great Elm Group, Inc.	2.15	-0.32	-12.96%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026

Synergy CHC AI Stock Analysis